Analysts who follow Puma Biotechnology Inc (PBYI) on average expect it to gain 150.71% over the next twelve months. Those same analysts give the stock an average rating of Buy.
That average rating earns PBYI an Analyst Ranking of 15, which means it ranks higher than 15 of stocks, based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers.
InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.
What’s Happening With Puma Biotechnology Inc Stock Today?
Puma Biotechnology Inc (PBYI) stock is unmoved 0% while the S&P 500 is up 1.32% as of 2:28 PM on Tuesday, Oct 18. PBYI is flat $0.00 from the previous closing price of $2.26 on volume of 74,338 shares. Over the past year the S&P 500 is down -16.94% while PBYI has fallen -61.82%. PBYI lost -$0.87 per share the over the last 12 months.
Click Here to get the full Stock Report for Puma Biotechnology Inc stock.
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Originally published at Melbourne News Vine
No comments:
Post a Comment